GlassScriptPhysician profile
Katherine Obryan
NPI 1447877279
$413.33
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $243.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.20 | 2021-2022 | |
| Novo Nordisk INC | $63.52 | 2021-2022 | |
| Lilly USA, LLC | $50.03 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $36.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.51 | 2022 | |
| Amgen INC. | $29.75 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $28.27 | 2022 | |
| Merck Sharp & Dohme LLC | $19.54 | 2021 | |
| Viiv Healthcare Company | $18.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.71 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.72 | 2021 | |
| Organon LLC | $3.29 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Obryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.